The research team analyzed price transparency data for 340B hospitals and found that across 59 oncology drugs, the lowest median markup was 2.4 times the 340B acquisition cost (Adcetris), and the highest was 11 times (Epogen).
They also found 340B hospitals don’t decrease the prices they charge insurers or patients when their acquisition prices decline, which nullifies efforts to reduce prices at the drugmaker level.
The finding researchers labeled “most problematic” was that 340B hospitals often charge their cash-paying customers the same as the median price for commercial insurers.
“In short, to the extent 340B institutions fulfill their mission of providing lower cost care, we are not seeing it reflected in their drug prices,” the researchers wrote.
Read the full report here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.